PURPOSE: The purpose of this study was to evaluate the appropriate 2-deoxy-2-[(18)F]fluoro-D-glucose-positron emission tomography (FDG-PET) determination in patients with inflammatory bowel disease (IBD) before and after clinical improvement to see if this determination correlates with clinical activity. PROCEDURES: We performed PET-computed tomography (PET/CT) on five patients before and after successful medical therapy in patients with moderately active IBD. Each patient had five bowel segments scored (0-3) for the appropriate FDG-PET determination. RESULTS: There were five patients [Crohn's disease (CD) = 3, ulcerative colitis = 2] who were studied an average of 437 days (range, 77-807) after initial PET/CT scan. All patients showed significant improvement in physician global assessment scores (p = 0.004) and underwent repeat PET/CT. The total score of all segments was 32 pretreatment and 14 posttreatment (p < 0.01). Of 11 pretreatment active segments, nine (82%) segments either became inactive or displayed decreased activity, while two showed no change (p < 0.001). CONCLUSION: Appropriate FDG-PET determination decreases with successful treatment of inflammation in active IBD and correlates with symptom improvement.
PURPOSE: The purpose of this study was to evaluate the appropriate 2-deoxy-2-[(18)F]fluoro-D-glucose-positron emission tomography (FDG-PET) determination in patients with inflammatory bowel disease (IBD) before and after clinical improvement to see if this determination correlates with clinical activity. PROCEDURES: We performed PET-computed tomography (PET/CT) on five patients before and after successful medical therapy in patients with moderately active IBD. Each patient had five bowel segments scored (0-3) for the appropriate FDG-PET determination. RESULTS: There were five patients [Crohn's disease (CD) = 3, ulcerative colitis = 2] who were studied an average of 437 days (range, 77-807) after initial PET/CT scan. All patients showed significant improvement in physician global assessment scores (p = 0.004) and underwent repeat PET/CT. The total score of all segments was 32 pretreatment and 14 posttreatment (p < 0.01). Of 11 pretreatment active segments, nine (82%) segments either became inactive or displayed decreased activity, while two showed no change (p < 0.001). CONCLUSION: Appropriate FDG-PET determination decreases with successful treatment of inflammation in active IBD and correlates with symptom improvement.
Authors: L Sutherland; J Singleton; J Sessions; S Hanauer; E Krawitt; G Rankin; R Summers; H Mekhjian; N Greenberger; M Kelly Journal: Gut Date: 1991-09 Impact factor: 23.059
Authors: Daniel A Lemberg; Robert M Issenman; Ruth Cawdron; Tim Green; John Mernagh; Stephen J Skehan; Claude Nahmias; Kevan Jacobson Journal: Inflamm Bowel Dis Date: 2005-08 Impact factor: 5.325
Authors: Betty S Pio; Fergus R Byrne; Richard Aranda; Guylain Boulay; Karsten Spicher; Mark H Song; Lutz Birnbaumer; Michael E Phelps; Johannes Czernin; Daniel H S Silverman Journal: Mol Imaging Biol Date: 2003 Jul-Aug Impact factor: 3.488
Authors: Randall S Meisner; Bret J Spier; Sigurdur Einarsson; Erica N Roberson; Scott B Perlman; Jesus A Bianco; Andrew J Taylor; Michael Einstein; Christine J Jaskowiak; Kathleen M Massoth; Mark Reichelderfer Journal: Inflamm Bowel Dis Date: 2007-08 Impact factor: 5.325
Authors: M F Neurath; D Vehling; K Schunk; M Holtmann; H Brockmann; A Helisch; T Orth; M Schreckenberger; P R Galle; P Bartenstein Journal: Am J Gastroenterol Date: 2002-08 Impact factor: 10.864
Authors: Debra J Caporizzo; Anna E Kwiatkowski; Ming-Kai Chen; Amanda P Beck; Carmen J Booth; Caroline Zeiss; Peter C Smith; Jodi A Carlson Scholz; Steven R Wilson Journal: Comp Med Date: 2014-06 Impact factor: 0.982
Authors: Onofrio Antonio Catalano; Vincent Wu; Umar Mahmood; Alberto Signore; Mark Vangel; Andrea Soricelli; Marco Salvatore; Debra Gervais; Bruce R Rosen Journal: Am J Nucl Med Mol Imaging Date: 2018-02-05
Authors: Robert T Lapp; Bret J Spier; Scott B Perlman; Christine J Jaskowiak; Mark Reichelderfer Journal: Mol Imaging Biol Date: 2011-06 Impact factor: 3.488
Authors: Yan Li; Benedikt Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Anna Katharina Koch; Ole Martin; Ken Herrmann; Hendrik Juette; Andrea Tannapfel; Jost Langhorst Journal: Eur J Nucl Med Mol Imaging Date: 2019-10-24 Impact factor: 9.236
Authors: Babak Saboury; Ali Salavati; Alex Brothers; Sandip Basu; Thomas C Kwee; Marnix G E H Lam; Roland Hustinx; Edouard Louis; Drew A Torigian; Abass Alavi Journal: Eur J Nucl Med Mol Imaging Date: 2013-11-20 Impact factor: 9.236